Sotera Health Company (SHC) Stock Forecast, Price Target & Predictions
SHC Stock Forecast
Sotera Health Company stock forecast is as follows: an average price target of $16.93 (represents a 0.77% upside from SHC’s last price of $16.80) and a rating consensus of 'Buy', based on 12 wall street analysts offering a 1-year stock forecast.
SHC Price Target
The average price target for Sotera Health Company (SHC) is $16.93 based on 1-year price targets from 12 Wall Street analysts in the past 3 months, with a price target range of $25.00 to $8.00. This represents a potential 0.77% upside from SHC's last price of $16.80.
SHC Analyst Ratings
According to 12 Wall Street analysts, Sotera Health Company's rating consensus is 'Buy'. The analyst rating breakdown for SHC stock is 0 'Strong Buy' (0.00%), 6 'Buy' (50.00%), 5 'Hold' (41.67%), 1 'Sell' (8.33%), and 0 'Strong Sell' (0.00%).
Sotera Health Company Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 06, 2024 | Luke Sergott | Barclays | $17.00 | $14.22 | 19.55% | 1.19% |
| Jun 06, 2024 | David Windley | Jefferies | $14.50 | $11.98 | 21.04% | -13.69% |
| May 21, 2024 | Jason Bednar | Piper Sandler | $13.00 | $10.91 | 19.16% | -22.62% |
| May 03, 2024 | Sean Dodge | RBC Capital | $17.00 | $10.91 | 55.82% | 1.19% |
| Apr 10, 2024 | Luke Sergott | Barclays | $14.00 | $11.62 | 20.48% | -16.67% |
| Mar 25, 2024 | David Windley | Jefferies | $15.50 | $11.94 | 29.87% | -7.74% |
| Jun 26, 2023 | Matthew Mishan | Loop Capital Markets | $24.00 | $18.59 | 29.14% | 42.86% |
| Jan 10, 2023 | Mike Polark | Wolfe Research | $25.00 | $17.25 | 44.93% | 48.81% |
| Jan 10, 2023 | Luke Sergott | Barclays | $22.00 | $17.25 | 27.54% | 30.95% |
| Nov 23, 2022 | - | Goldman Sachs | $8.00 | $8.12 | -1.42% | -52.38% |
The latest Sotera Health Company stock forecast, released on Aug 06, 2024 by Luke Sergott from Barclays, set a price target of $17.00, which represents a 19.55% increase from the stock price at the time of the forecast ($14.22), and a 1.19% increase from SHC last price ($16.80).
Sotera Health Company Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 6 |
| Avg Price Target | - | $17.00 | $15.17 |
| Last Closing Price | $16.80 | $16.80 | $16.80 |
| Upside/Downside | -100.00% | 1.19% | -9.70% |
In the current month, the average price target of Sotera Health Company stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Sotera Health Company's last price of $16.80. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 06, 2024 | Barclays | Overweight | Overweight | Hold |
| Aug 05, 2024 | KeyBanc | Sector Weight | Sector Weight | Hold |
| Jun 06, 2024 | Jefferies | Buy | Buy | Hold |
| May 21, 2024 | RBC Capital | Buy | Buy | Hold |
| May 21, 2024 | Piper Sandler | - | Neutral | Initialise |
| May 03, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Apr 03, 2024 | Jefferies | Underperform | Underperform | Hold |
| Apr 03, 2024 | RBC Capital | Buy | Buy | Hold |
| Apr 03, 2024 | Citigroup | Neutral | Buy | Upgrade |
| Mar 25, 2024 | Jefferies | - | Buy | Upgrade |
Sotera Health Company's last stock rating was published by Barclays on Aug 06, 2024. The company gave SHC a "Overweight" rating, the same as its previous rate.
Sotera Health Company Financial Forecast
Sotera Health Company Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $310.24M | $263.18M | $255.28M | $220.59M | $251.59M | $248.70M | - | $236.75M | $241.25M | $226.16M | $251.92M | $212.15M | $216.84M |
| Avg Forecast | $333.85M | $327.63M | $321.52M | $315.53M | $323.56M | $296.39M | $295.13M | $262.84M | $301.81M | $278.28M | $266.45M | $244.38M | $302.17M | $264.55M | $258.93M | $221.03M | $247.46M | $248.20M | $256.30M | $230.17M | $236.37M | $221.61M | $227.24M | $207.38M | $209.12M |
| High Forecast | $337.11M | $330.83M | $324.66M | $318.61M | $326.73M | $299.29M | $298.01M | $265.41M | $304.76M | $280.57M | $269.06M | $246.76M | $303.65M | $267.14M | $261.46M | $223.19M | $249.88M | $250.63M | $256.30M | $237.70M | $244.11M | $228.86M | $234.68M | $214.17M | $215.97M |
| Low Forecast | $331.34M | $325.17M | $319.11M | $313.16M | $321.13M | $294.17M | $292.91M | $260.87M | $299.54M | $275.46M | $264.45M | $242.54M | $300.70M | $262.56M | $256.98M | $219.37M | $245.60M | $246.34M | $256.30M | $222.34M | $228.34M | $214.07M | $219.52M | $200.33M | $202.01M |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.03% | 0.99% | 0.99% | 1.00% | 1.02% | 1.00% | - | 1.03% | 1.02% | 1.02% | 1.11% | 1.02% | 1.04% |
Sotera Health Company's average Quarter revenue forecast for Mar 24 based on 2 analysts is $244.38M, with a low forecast of $242.54M, and a high forecast of $246.76M. SHC's average Quarter revenue forecast represents a -21.23% decrease compared to the company's last Quarter revenue of $310.24M (Dec 23).
Sotera Health Company EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $104.02M | $76.10M | $81.78M | $50.85M | $78.02M | $101.01M | - | $92.51M | $74.34M | $96.88M | $118.41M | $72.80M | $49.15M |
| Avg Forecast | $129.94M | $127.52M | $125.14M | $122.81M | $125.94M | $115.36M | $114.87M | $102.30M | $117.47M | $108.31M | $103.71M | $95.12M | $117.61M | $102.97M | $100.78M | $86.03M | $96.32M | $100.96M | $99.76M | $81.53M | $92.00M | $91.78M | $81.01M | $63.70M | $81.40M |
| High Forecast | $131.21M | $128.77M | $126.37M | $124.01M | $127.17M | $116.49M | $115.99M | $103.30M | $118.62M | $109.20M | $104.72M | $96.05M | $118.19M | $103.98M | $101.77M | $86.87M | $97.26M | $121.15M | $99.76M | $97.83M | $95.01M | $110.13M | $97.22M | $76.44M | $84.06M |
| Low Forecast | $128.97M | $126.56M | $124.20M | $121.89M | $124.99M | $114.50M | $114.01M | $101.54M | $116.59M | $107.22M | $102.93M | $94.40M | $117.04M | $102.20M | $100.02M | $85.38M | $95.59M | $80.76M | $99.76M | $65.22M | $88.87M | $73.42M | $64.81M | $50.96M | $78.63M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.88% | 0.74% | 0.81% | 0.59% | 0.81% | 1.00% | - | 1.13% | 0.81% | 1.06% | 1.46% | 1.14% | 0.60% |
2 analysts predict SHC's average Quarter EBITDA for Mar 24 to be $95.12M, with a high of $96.05M and a low of $94.40M. This is -8.56% lower than Sotera Health Company's previous annual EBITDA (Dec 23) of $104.02M.
Sotera Health Company Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $38.68M | $-13.66M | $23.51M | $2.84M | $-319.72M | $25.09M | - | $30.64M | $36.00M | $27.44M | $42.60M | $10.84M | $-43.68M |
| Avg Forecast | $84.62M | $76.48M | $64.51M | $49.94M | $74.93M | $61.65M | $59.43M | $40.69M | $62.77M | $51.73M | $46.86M | $35.35M | $73.34M | $56.32M | $52.05M | $38.71M | $62.34M | $28.60M | $68.76M | $27.24M | $62.75M | $26.00M | $29.15M | $9.49M | $21.28M |
| High Forecast | $85.70M | $77.46M | $65.32M | $50.57M | $75.88M | $62.43M | $60.18M | $41.21M | $63.57M | $52.39M | $47.45M | $35.80M | $78.98M | $57.03M | $52.71M | $39.20M | $63.13M | $34.32M | $68.76M | $32.68M | $65.42M | $31.20M | $34.98M | $11.38M | $22.18M |
| Low Forecast | $83.80M | $75.74M | $63.88M | $49.45M | $74.20M | $61.05M | $58.85M | $40.29M | $62.16M | $49.01M | $46.40M | $35.00M | $70.52M | $55.77M | $51.54M | $38.33M | $61.73M | $22.88M | $68.76M | $21.79M | $59.98M | $20.80M | $23.32M | $7.59M | $20.34M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.53% | -0.24% | 0.45% | 0.07% | -5.13% | 0.88% | - | 1.13% | 0.57% | 1.06% | 1.46% | 1.14% | -2.05% |
Sotera Health Company's average Quarter net income forecast for Mar 24 is $35.35M, with a range of $35.00M to $35.80M. SHC's average Quarter net income forecast represents a -8.62% decrease compared to the company's last Quarter net income of $38.68M (Dec 23).
Sotera Health Company SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $60.36M | $54.11M | $60.29M | $61.91M | $65.95M | $57.09M | - | $59.54M | $51.83M | $44.04M | $49.83M | $52.47M | $68.20M |
| Avg Forecast | $67.75M | $66.49M | $65.25M | $64.04M | $65.67M | $60.15M | $59.90M | $53.34M | $61.25M | $56.48M | $54.08M | $49.60M | $61.33M | $53.69M | $52.55M | $44.86M | $50.22M | $45.89M | $52.02M | $52.93M | $47.97M | $41.72M | $34.09M | $45.91M | $42.44M |
| High Forecast | $68.42M | $67.14M | $65.89M | $64.66M | $66.31M | $60.74M | $60.48M | $53.86M | $61.85M | $56.94M | $54.61M | $50.08M | $61.63M | $54.22M | $53.06M | $45.30M | $50.71M | $55.07M | $52.02M | $63.51M | $49.54M | $50.06M | $40.91M | $55.09M | $43.83M |
| Low Forecast | $67.25M | $65.99M | $64.76M | $63.56M | $65.17M | $59.70M | $59.45M | $52.94M | $60.79M | $55.90M | $53.67M | $49.22M | $61.03M | $53.29M | $52.15M | $44.52M | $49.84M | $36.71M | $52.02M | $42.34M | $46.34M | $33.38M | $27.27M | $36.73M | $41.00M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.98% | 1.01% | 1.15% | 1.38% | 1.31% | 1.24% | - | 1.13% | 1.08% | 1.06% | 1.46% | 1.14% | 1.61% |
Sotera Health Company's average Quarter SG&A projection for Mar 24 is $49.60M, based on 2 Wall Street analysts, with a range of $49.22M to $50.08M. The forecast indicates a -17.83% fall compared to SHC last annual SG&A of $60.36M (Dec 23).
Sotera Health Company EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $0.14 | $-0.05 | $0.08 | $0.01 | $-1.14 | $0.09 | - | $0.11 | $0.13 | $0.10 | $0.15 | $0.04 | $-0.17 |
| Avg Forecast | $0.30 | $0.27 | $0.23 | $0.18 | $0.26 | $0.22 | $0.21 | $0.14 | $0.22 | $0.18 | $0.16 | $0.12 | $0.26 | $0.20 | $0.18 | $0.14 | $0.22 | $0.22 | $0.24 | $0.19 | $0.22 | $0.20 | $0.21 | $0.16 | $0.08 |
| High Forecast | $0.30 | $0.27 | $0.23 | $0.18 | $0.27 | $0.22 | $0.21 | $0.14 | $0.22 | $0.18 | $0.17 | $0.13 | $0.28 | $0.20 | $0.19 | $0.14 | $0.22 | $0.23 | $0.24 | $0.20 | $0.23 | $0.21 | $0.22 | $0.17 | $0.08 |
| Low Forecast | $0.29 | $0.27 | $0.22 | $0.17 | $0.26 | $0.21 | $0.21 | $0.14 | $0.22 | $0.17 | $0.16 | $0.12 | $0.25 | $0.20 | $0.18 | $0.13 | $0.22 | $0.22 | $0.24 | $0.18 | $0.21 | $0.19 | $0.20 | $0.16 | $0.07 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.54% | -0.25% | 0.44% | 0.07% | -5.20% | 0.40% | - | 0.57% | 0.59% | 0.49% | 0.72% | 0.25% | -2.26% |
According to 2 Wall Street analysts, Sotera Health Company's projected average Quarter EPS for Mar 24 is $0.12, with a low estimate of $0.12 and a high estimate of $0.13. This represents a -11.27% decrease compared to SHC previous annual EPS of $0.14 (Dec 23).
Sotera Health Company Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ACRS | Aclaris Therapeutics | $1.18 | $25.00 | 2018.64% | Buy |
| GTH | Genetron | $4.03 | $10.00 | 148.14% | - |
| XGN | Exagen | $2.96 | $6.00 | 102.70% | Buy |
| MEDP | Medpace | $351.67 | $444.20 | 26.31% | Buy |
| QGEN | Qiagen | $46.36 | $52.37 | 12.96% | Buy |
| IQV | IQVIA | $238.70 | $269.43 | 12.87% | Buy |
| NEOG | Neogen | $16.13 | $17.50 | 8.49% | Buy |
| ICLR | ICON Public Limited Company | $300.00 | $307.63 | 2.54% | Buy |
| SHC | Sotera Health Company | $16.80 | $16.93 | 0.77% | Buy |
| MYGN | Myriad Genetics | $27.59 | $27.67 | 0.29% | Hold |
| RDNT | RadNet | $67.79 | $59.67 | -11.98% | Buy |
| OLK | Olink AB (publ) | $26.08 | $21.50 | -17.56% | Hold |
SHC Forecast FAQ
Is Sotera Health Company a good buy?
Yes, according to 12 Wall Street analysts, Sotera Health Company (SHC) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 50.00% of SHC's total ratings.
What is SHC's price target?
Sotera Health Company (SHC) average price target is $16.93 with a range of $8 to $25, implying a 0.77% from its last price of $16.8. The data is based on 12 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Sotera Health Company stock go up soon?
According to Wall Street analysts' prediction for SHC stock, the company can go up by 0.77% (from the last price of $16.8 to the average price target of $16.93), up by 48.81% based on the highest stock price target, and down by -52.38% based on the lowest stock price target.
Can Sotera Health Company stock reach $30?
SHC's average twelve months analyst stock price target of $16.93 does not support the claim that Sotera Health Company can reach $30 in the near future.
What are Sotera Health Company's analysts' financial forecasts?
Sotera Health Company's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.18B (high $1.19B, low $1.17B), average EBITDA is $458.48M (high $462.96M, low $455.03M), average net income is $236.7M (high $239.71M, low $234.39M), average SG&A $239.06M (high $241.4M, low $237.26M), and average EPS is $0.832 (high $0.842, low $0.824). SHC's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $1.3B (high $1.31B, low $1.29B), average EBITDA is $505.42M (high $510.36M, low $501.62M), average net income is $275.55M (high $279.05M, low $272.86M), average SG&A $263.53M (high $266.11M, low $261.56M), and average EPS is $0.968 (high $0.981, low $0.959).
Did the SHC's actual financial results beat the analysts' financial forecasts?
Based on Sotera Health Company's last annual report (Dec 2023), the company's revenue was $1.05B, beating the average analysts forecast of $1.05B by 0.25%. Apple's EBITDA was $276.69M, missing the average prediction of $407.39M by -32.08%. The company's net income was $51.38M, missing the average estimation of $220.42M by -76.69%. Apple's SG&A was $236.67M, beating the average forecast of $212.42M by 11.41%. Lastly, the company's EPS was $0.18, missing the average prediction of $0.775 by -76.76%. In terms of the last quarterly report (Dec 2023), Sotera Health Company's revenue was $310.24M, beating the average analysts' forecast of $302.17M by 2.67%. The company's EBITDA was $104.02M, missing the average prediction of $117.61M by -11.55%. Sotera Health Company's net income was $38.68M, missing the average estimation of $73.34M by -47.26%. The company's SG&A was $60.36M, missing the average forecast of $61.33M by -1.58%. Lastly, the company's EPS was $0.14, missing the average prediction of $0.258 by -45.68%